FAQ

ETP-46321

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
01220122016

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyrazines

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
ETP-46321
Imidazoles
Pyrazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Identification of novel PI3K inhibitors through a scaffold hopping strategy.
A scaffold hopping strategy, including intellectual property availability assessment, was successfully applied for the discovery… (More)
Is this relevant?
2017
2017
Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
The involvement of the phosphoinositide 3-kinases (PI3Ks) in several diseases, especially in the oncology area, has singled it as… (More)
Is this relevant?
2016
2016
ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses… (More)
Is this relevant?
2012
2012
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of this signaling pathway… (More)
Is this relevant?
2012
2012
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
Inhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling pathway is… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?